2025 United States Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report
Description
The 2025 United States Artificial Intelligence (Ai) In Drug Discovery Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States AI in drug discovery market are Isomorphic Labs (Google DeepMind's sister company), Exscientia, Recursion Pharmaceuticals, and Atomwise. Isomorphic Labs pioneers AI-driven drug design, leveraging breakthroughs like AlphaFold3, and holds high-value collaborations with Eli Lilly and Novartis. Exscientia partners with AWS to integrate AI and machine learning throughout drug discovery pipelines, enhancing automation and generative capabilities. Recursion Pharmaceuticals combines AI, automation, and high-throughput biology, focusing on rare diseases and has significant partnerships with Roche, Genentech, Bayer, and NVIDIA for accelerating drug discovery using AI. Atomwise applies structure-based deep learning with its AtomNet™ platform to improve drug-target interaction prediction, collaborating across therapeutic areas including oncology and infectious diseases.
These companies embody innovation by integrating AI to accelerate drug discovery, reduce costs, and improve efficacy. Isomorphic Labs' AlphaFold3 model revolutionizes protein structure prediction, Exscientia extends AI to synthesis automation, Recursion's AI-enabled biology maps streamline therapeutic candidate identification, and Atomwise's deep learning supports computational chemistry precision. Together, they drive the US market dominance (69% market share in 2022) in AI drug discovery, supported by strong R&D investments and strategic pharma partnerships that aim to shorten drug development timelines and address complex diseases efficiently.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Artificial Intelligence (AI) in Drug Discovery Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States AI in drug discovery market are Isomorphic Labs (Google DeepMind's sister company), Exscientia, Recursion Pharmaceuticals, and Atomwise. Isomorphic Labs pioneers AI-driven drug design, leveraging breakthroughs like AlphaFold3, and holds high-value collaborations with Eli Lilly and Novartis. Exscientia partners with AWS to integrate AI and machine learning throughout drug discovery pipelines, enhancing automation and generative capabilities. Recursion Pharmaceuticals combines AI, automation, and high-throughput biology, focusing on rare diseases and has significant partnerships with Roche, Genentech, Bayer, and NVIDIA for accelerating drug discovery using AI. Atomwise applies structure-based deep learning with its AtomNet™ platform to improve drug-target interaction prediction, collaborating across therapeutic areas including oncology and infectious diseases.
These companies embody innovation by integrating AI to accelerate drug discovery, reduce costs, and improve efficacy. Isomorphic Labs' AlphaFold3 model revolutionizes protein structure prediction, Exscientia extends AI to synthesis automation, Recursion's AI-enabled biology maps streamline therapeutic candidate identification, and Atomwise's deep learning supports computational chemistry precision. Together, they drive the US market dominance (69% market share in 2022) in AI drug discovery, supported by strong R&D investments and strategic pharma partnerships that aim to shorten drug development timelines and address complex diseases efficiently.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
